Amide Proton Transfer (APT) MRI of Brain Tumors at 3T and 7T

3T 和 7T 脑肿瘤的酰胺质子转移 (APT) MRI

• 批准号: 8245046
• 负责人: JINYUAN ZHOU
• 金额: $ 35.04万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2013-09-22
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8245046
• 关键词: Amides; Anaplastic astrocytoma; Area; Attenuated; Biometry; Blood - brain barrier anatomy; Body Image; Brain; Brain Diseases; Brain Neoplasms; Brain imaging; Cells; Cellularity; Chemicals; Clinic; Clinical; Clinical Data; Clinical Management; Coiled Bodies; Cytoplasm; Data; Detection; Diagnosis; Diagnostic; Diffusion; Edema; Etiology; Eye; Frequencies; Future; Gadolinium; Glioblastoma; Glioma; Goals; Health; Histologic; Image; Image Guided Biopsy; Imaging Techniques; Injury; Kidney; Liquid substance; Local Therapy; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant - descriptor; Malignant Glioma; Malignant Neoplasms; Malignant neoplasm of brain; Methodology; Necrosis; Noise; Operative Surgical Procedures; Pathology; Patients; Peptides; Perfusion; Physics; Physiologic pulse; Proteins; Proteomics; Protocols documentation; Protons; Radiation; Radiation therapy; Radiosurgery; Recovery; Risk; Scanning; Scientist; Sensitivity and Specificity; Signal Transduction; Slice; Specificity; Techniques; Technology; Testing; Time; Tissues; Validation; Visual; Work; absorption; base; chemotherapy; clinical application; computerized data processing; design; diagnostic accuracy; gadolinium oxide; improved; in vivo; magnetic field; molecular/cellular imaging; multidisciplinary; neuroimaging; neurosurgery; novel; novel therapeutics; oncology; preclinical study; programs; radiofrequency; response; treatment planning; tumor; tumor progression

DESCRIPTION (provided by applicant): Malignant brain tumors remain one of the deadliest forms of cancer despite maximal surgical intervention, radiation therapy and chemotherapy. Limitations in neuroimaging technology complicate the clinical management of patients with gliomas and impede efficient testing of new therapeutics. Recently, we have designed a new magnetization transfer-based MRI technique, dubbed amide proton transfer (APT) imaging, that detects a variety of amide protons of endogenous mobile proteins and peptides, such as those in the cytoplasm. Our preclinical studies and pilot clinical data using single-slice acquisition suggest that APT may provide unique information about the presence and grade of brain tumors based on increased cellular content of proteins and peptides, as revealed by MRI-guided proteomics and in vivo MR spectroscopy. However, many technical problems have to be resolved before this technique can be applied reliably for whole-brain imaging in a clinical setting. The overall goals of this proposal are to develop a fast whole-brain APT methodology for use in the clinic and to assess the capability for APT to provide unique visual data about heterogeneous portions of gliomas when compared to standard MRI sequences. To achieve this goal, we have assembled a multidisciplinary team of basic scientists and clinicians, within the framework of a national brain cancer program, who will each contribute their particular expertise in the fields of physics, biostatistics, oncology, neurosurgery, pathology, and neuroradiology. Our specific aims are: (1) Develop a time-efficient whole-brain APT imaging technique at 3T for clinical application, (2) Determine the sensitivity and specificity of APT imaging at 3T in evaluating heterogeneous brain tumors by distinguishing tumor core from peritumoral edema and low- from high-grade gliomas, (3) Explore the origin of the APT contrast for brain tumors using APT-image guided biopsy to allow histologic validation, and (4) explore the feasibility and optimal quality of APT imaging at 7T. This work has the potential to yield a clinically applicable new MRI technique that is unique in its ability to image tissue at the protein and peptide level. This may improve the diagnostic accuracy of brain MRI for malignant gliomas and, potentially, other diseases of the brain and, hence, is of enormous clinical importance. PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a novel protein and peptide-based MRI technique, called amide proton transfer (APT) imaging, and to determine the sensitivity and specificity of APT imaging for the detection of brain tumors. APT-MRI may improve the diagnostic and surgical accuracy in treating malignant gliomas.

描述（由申请人提供）：尽管最大的手术干预，放射治疗和化学疗法，但恶性脑肿瘤仍然是最致命的癌症形式之一。神经影像技术的局限性使神经胶质瘤患者的临床管理变得复杂，并阻碍了对新疗法的有效测试。最近，我们设计了一种新的基于磁化转移的MRI技术，称为酰胺质子转移（APT）成像，该技术检测了内源性移动蛋白和肽的各种酰胺质子，例如细胞质中的酰胺质子。我们使用单板采集的临床前研究和试验临床数据表明，根据MRI引导的蛋白质组学和体内MR光谱学揭示，基于蛋白质和肽的细胞含量增加，基于蛋白质和肽的细胞含量增加，可以提供有关脑肿瘤的存在和等级的独特信息。但是，必须解决许多技术问题，然后才能可靠地应用于临床环境中的全脑成像。该提案的总体目标是开发一种快速的全脑合适方法，用于在诊所中使用，并评估与标准MRI序列相比，可与胶质瘤的异质部分提供独特的视觉数据的能力。为了实现这一目标，我们在国家脑癌计划的框架内组建了一个基础科学家和临床医生组成的多学科团队，他们将在物理学，生物统计学，肿瘤学，神经外科，病理学和神经放射学领域中各自贡献其特定的专业知识。我们的具体目的是：（1）在3T时在3T处开发一种时间效率的全脑APT成像技术，（2）在评估肿瘤核心的敏感性和特异性，在评估3T时的敏感性和特异性，通过将肿瘤核心核心与外腹水肿和低级别的指示性的指示相识别，（3）探索脑外周的肿瘤核心，（3）探索脑外周的脑肿瘤，（3）为了允许组织学验证，（4）探索7T时APT成像的可行性和最佳质量。这项工作有可能产生一种临床上适用的新MRI技术，该技术在蛋白质和肽水平的组织能力方面具有独特性。这可能会提高大脑MRI对恶性神经胶质瘤的诊断准确性，并可能提高大脑的其他疾病，因此具有巨大的临床重要性。公共卫生相关性：该项目的目的是开发一种新型的蛋白质和基于肽的MRI技术，称为酰胺质子转移（APT）成像，并确定APT成像对检测脑肿瘤的敏感性和特异性。 APT-MRI可以提高治疗恶性神经胶质瘤的诊断和手术准确性。